University of British Columbia news release
The HPV vaccine provides strong, long-lasting protection for women living with HIV, study finds.
The findings provide important new evidence as countries work toward the World Health Organization’s goal of eliminating cervical cancer. Women living with HIV are six times more likely to be infected with HPV and twice as likely to die from invasive cervical cancer than those without HIV, making vaccination particularly important for this population.
Published in The Lancet HIV, the study followed women living with HIV for up to nine years after HPV vaccination — the longest study to date examining how well the vaccine works in this population. Until now, researchers had little evidence about the vaccine’s effectiveness in women living with HIV beyond two years.
Read the full news release here.
Source : University of British Columbia
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.